Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575275 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29402209 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29383097 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119365 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30510359 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29447672 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL17359219 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30792899 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL27028706 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119560 | 0.96 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | ALDH1A1 4421/4885SMN1; SMN2 1404/4885RAB9A 3415/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | ALDH1A1 2138/4885SMN1; SMN2 3692/4885RAB9A 2038/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | ALDH1A1 1732/4885SMN1; SMN2 3140/4885RAB9A 649/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ALDH1A1 4740/4885SMN1; SMN2 4314/4885RAB9A 2400/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | ALDH1A1 2546/4885SMN1; SMN2 1943/4885RAB9A 2724/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | ALDH1A1 3038/4885SMN1; SMN2 498/4885RAB9A 1603/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ALDH1A1 4760/4885SMN1; SMN2 4117/4885RAB9A 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.